Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations


Next generation sequencing (NGS) methods have allowed for unprecedented genomic characterization of acute myeloid leukemia (AML) over the last several years. Further advances in NGS-based methods including error correction using unique molecular identifiers (UMIs) have more recently enabled the use of NGS-based measurable residual disease (MRD) detection. This review focuses on the use of NGS-based MRD detection in AML, including basic methodologies and clinical applications.

Original languageEnglish
Article number249
JournalFrontiers in Cell and Developmental Biology
StatePublished - May 8 2020


  • acute myeloid leukemia
  • clinical applications of NGS
  • error-corrected sequencing
  • measurable (minimal) residual disease
  • next generation sequencing
  • unique molecular identifier


Dive into the research topics of 'Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this